Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma

What this Trial Is About

Researchers are evaluating whether cardiac autonomic dysfunction (AD) can be diagnosed remotely with the same accuracy as traditional in-person testing. This study focuses on survivors of childhood cancers such as acute lymphoblastic leukemia and Hodgkin's lymphoma, who appear to have a higher risk of AD. The goal is to find out if remote methods can identify AD sooner, potentially allowing for earlier interventions and reducing illness risk. Participants undergo an in-person clinical assessment called the Ewing battery, which takes 60 to 90 minutes and measures heart rate and blood pressure changes during various activities. They are asked to avoid aspirin, ibuprofen, acetaminophen, alcohol, caffeine, and smoking for specific periods before testing. After the visit, participants wear a wrist biosensor device for 7 days to remotely monitor heart rate variability and complete a symptom questionnaire called COMPASS31 either before or after the in-person assessment. Throughout the study, participants will have their heart rate variability monitored remotely for up to 7 days following the clinic visit. The research team will compare remote biosensor measurements and questionnaire results against the in-person Ewing battery to assess accuracy. The study measures include heart rate variability data, symptom scores, and Ewing scores collected during the visit. This design helps understand if remote monitoring can effectively detect AD in this population.

Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma